Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features

Table 1

Clinical baseline features.

	Control group ()	Study group ()	/
Age (, years)			0.491	0.625
Gender ()			1.169	0.280
Male	32	37
Female	18	13
Smoking ()			0.361	0.548
Yes	25	22
No	25	28
Histology ()			0.480	0.488
Squamous	11	14
Nonsquamous	39	36
Brain metastasis ()			0.832	0.362
Yes	15	11
No	35	39
Stage ()			0.679	0.410
III	17	21
IV	33	29
ECOG score ()			0.683	0.711
1	9	7
2	24	28
3	17	15

ECOG: Eastern Cooperative Oncology Group.